EUCTR2014-002539-32-FR进行中（未招募）1 期
Does botulinum toxin A make walking easier i in children with cerebral palsy?
St. Olavs University Hospital0 个研究点目标入组 96 人开始时间: 2018年7月16日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Eligible to participate in the study are children and adolescents with spastic cerebral palsy referred to the out-patient clinics at the participating sites and regional partners, for injection of BoNT-A in the calf muscles.
- •All of the following conditions must apply to the prospective patient at screening prior to receiving study agent (e.g.):
- •Diagnosed with unilateral or bilateral CP in their medical record
- •GMFCS level I and II
- •Must be at least 4 years of age.
- •Spasticity in the calf muscles, clinically judged as grade 2 or 3 (the presence of a spastic catch) according to the Tardieu Scale.
- •Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 14
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will be excluded from the study if they meet any of the following criteria:
- •BoNT-A injections in the lower limbs in the last 6 months before intervention
- •History of adverse reactions to BoNT-A
- •Known hypersensitivity to BoNT-A or to any of the excipients
- •Orthopedic surgery in the lower limbs in the last 2 years
- •Major cognitive impairments (must be able to take verbal instructions and conduct the test procedure)
- •Presence of infection at the proposed injection site(s)
- •Subclinical or clinical evidence of defective neuromuscular transmission e.g. myasthenia gravis or Lambert-Eaton Syndrome in patients with peripheral motor neuropathic diseases (e.g. amyotrophic lateral sclerosis or motor neuropathy) or other underlying neurological disorders that may be affected by BoNT-A injections
- •Use of aminoglycoside antibiotics or spectinomycin, or other medicinal products that interfere with neuromuscular transmission (e.g. neuromuscular blocking agents)
- •Pregnant or breast-feeding
- •Childbearing potential not using contraception
- •Any reason why, in the opinion of the investigator, the patient should not participate
- •Patients with pre-existing swallowing or breathing problems
- •Patients with pre-existing cardiovascular disease
研究者
相似试验
尚未招募
3 期
The proposed study will answer the key question whether Botulinum toxin injection in the spastic (tight) lower limb muscles following stroke improves walking and the quality of life.Post stroke lower limb spasticitySpasticityLower limb spasticityStrokeACTRN12617001603303The Hospital Research Foundation80
进行中（未招募）
1 期
Can local botulinum toxin improve swallowing difficulties in persons with msucle disease?Oculopharyngesl muscle dystrophy, inclusion body myositisMedDRA version: 18.1 Level: LLT Classification code 10019897 Term: Hereditary progressive muscular dystrophy System Organ Class: 100000004850EUCTR2014-002210-23-DKRigshospitalet15
招募中
2 期
The effect of Botulinum type A on sialorrhea in patients with cerebral palsyCerebral palsycerebral palsysialorrhea.IRCT20220211053995N1Mashhad University of Medical Sciences20
尚未招募
2 期
Investigating the effect of botulinum toxin on parotidectomyIRCT20210923052559N2Mashhad University of Medical Sciences100
已完成
4 期
Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy?Muscle SpasticityCerebral PalsyNCT02546999St. Olavs Hospital61